WallStreetZenWallStreetZen

NASDAQ: MDGL
Madrigal Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for MDGL

Based on 6 analysts offering 12 month price targets for Madrigal Pharmaceuticals Inc.
Min Forecast
$224.00+5.11%
Avg Forecast
$304.67+42.96%
Max Forecast
$383.00+79.71%

Should I buy or sell MDGL stock?

Based on 6 analysts offering ratings for Madrigal Pharmaceuticals Inc.
Buy
Strong Buy
1 analysts 16.67%
Buy
4 analysts 66.67%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MDGL stock forecasts and price targets.

MDGL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-14
lockedlocked$00.00+00.00%2023-11-13
lockedlocked$00.00+00.00%2023-09-19
lockedlocked$00.00+00.00%2023-09-11
lockedlocked$00.00+00.00%2023-08-09
Canaccord Genuity
Bottom 11%
11
Strong BuyReiterates$336.00+65.27%2023-07-18

1 of 1

Forecast return on equity

Is MDGL forecast to generate an efficient return?
Company
N/A
Industry
-0.68%
Market
30.08%

Forecast return on assets

Is MDGL forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.19%

MDGL revenue forecast

What is MDGL's revenue in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$192.3M
Avg 2 year Forecast
$614.6M
Avg 3 year Forecast
$1.3B

MDGL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MDGL$203.30$304.67+49.86%Buy
MRTX$56.75$59.14+4.22%Buy
NUVL$65.37$60.50-7.45%Strong Buy
BPMC$69.64$73.33+5.30%Buy
ACAD$22.28$33.33+49.61%Buy

Madrigal Pharmaceuticals Stock Forecast FAQ

Is Madrigal Pharmaceuticals Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: MDGL) stock is to Buy MDGL stock.

Out of 6 analysts, 1 (16.67%) are recommending MDGL as a Strong Buy, 4 (66.67%) are recommending MDGL as a Buy, 1 (16.67%) are recommending MDGL as a Hold, 0 (0%) are recommending MDGL as a Sell, and 0 (0%) are recommending MDGL as a Strong Sell.

If you're new to stock investing, here's how to buy Madrigal Pharmaceuticals stock.

What is MDGL's revenue growth forecast for 2024-2026?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.51%.

Madrigal Pharmaceuticals's revenue in 2023 is $0.On average, 7 Wall Street analysts forecast MDGL's revenue for 2024 to be $3,795,958,032, with the lowest MDGL revenue forecast at $1,708,923,438, and the highest MDGL revenue forecast at $8,344,229,332. On average, 6 Wall Street analysts forecast MDGL's revenue for 2025 to be $12,134,185,599, with the lowest MDGL revenue forecast at $6,329,689,734, and the highest MDGL revenue forecast at $22,439,294,017.

In 2026, MDGL is forecast to generate $24,762,608,598 in revenue, with the lowest revenue forecast at $18,367,965,559 and the highest revenue forecast at $35,642,188,530.

What is MDGL's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: MDGL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.19%.

What is MDGL's Price Target?

According to 6 Wall Street analysts that have issued a 1 year MDGL price target, the average MDGL price target is $304.67, with the highest MDGL stock price forecast at $383.00 and the lowest MDGL stock price forecast at $224.00.

On average, Wall Street analysts predict that Madrigal Pharmaceuticals's share price could reach $304.67 by Nov 14, 2024. The average Madrigal Pharmaceuticals stock price prediction forecasts a potential upside of 49.86% from the current MDGL share price of $203.30.

What is MDGL's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: MDGL) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.